Winnipeg, Manitoba — October 16, 2025 — Leads & Copy — Cytophage Technologies Ltd. has partnered with W.L.T. Distributors Inc. to distribute OvaPhage, a bacteriophage product designed to reduce Salmonella load on egg shells, across Canada. This announcement follows Cytophage’s recent receipt of Health Canada’s Letter of No Objection (LONO) for the sale of OvaPhage.
Dr. Steven Theriault, CEO of Cytophage Technologies, expressed excitement about the partnership, highlighting WLT’s market knowledge and expertise. James Hokanson, COO of WLT, emphasized the importance of innovative and sustainable products in the industry.
According to Statistics Canada, the egg industry in Canada produced over 915 million dozen eggs in 2024. Cytophage and WLT aim to make OvaPhage broadly accessible to egg producers across Canada.
WLT has been sourcing and supplying feed ingredients and agricultural products to farms for over 40 years and has a team with 50 years of experience in the poultry industry in Canada.
Cytophage Technologies is a biotechnology company dedicated to bacteriophage research, product development, and commercialization, addressing the global challenge of antibiotic resistance.
Heather Medwick, Chief Operating Officer, heather@cytophage.com
Source: Cytophage Technologies Ltd.
